NCT05952661 (ECMRD-001) is a clinical trial in Esophageal Carcinoma, sponsored by Hebei Medical University Fourth Hospital.

Who is sponsoring NCT05952661?

NCT05952661 is sponsored by Hebei Medical University Fourth Hospital.

What condition does NCT05952661 study?

NCT05952661 studies Esophageal Carcinoma, Minimal Residual Disease.

Is NCT05952661 still recruiting?

NCT05952661 is currently recruiting now. Last updated 19 July 2023.

Last reviewed 2023-07-19 · How we verify

NCT05952661: ECMRD-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Minimally Residual of Esophageal Cancer 001

Recruiting now Last updated 19 July 2023

What this trial tests

trial in Esophageal Carcinoma in 56 participants. Currently enrolling.

Timeline

22 February 2023

Primary endpoint
31 December 2024

31 December 2027

Quick facts

Lead sponsor	Hebei Medical University Fourth Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	56
Start date	22 February 2023
Primary completion	31 December 2024
Estimated completion	31 December 2027
Sites	1 location across China

Conditions studied

Esophageal Carcinoma — all drugs for Esophageal Carcinoma →
Minimal Residual Disease — all drugs for Minimal Residual Disease →

Sponsor

Hebei Medical University Fourth Hospital

Who can join

Adults 18 to 75, any sex, with Esophageal Carcinoma or Minimal Residual Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial aims to assess changes in minimal residual disease (MRD) status before and after radical concurrent chemoradiotherapy combined with immunotherapy and adjuvant immunotherapy after neoadjuvant immunochemotherapy in patients with inoperable stage II-III esophageal squamous cell cancer (ESCC), and correlate with the efficacy of adjuvant immunotherapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, et al · · 2025 · cited 6× · PMID 39920551 · DOI 10.1007/s10147-024-02683-0
Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
Wang H, Zhang X, Zhao X, Song C, et al · · 2023 · cited 5× · PMID 38274807 · DOI 10.3389/fimmu.2023.1330928
The dual nature of immunotherapy in female reproductive disorders: immune homeostasis and clinical challenges.
Abulajiang Y, Wu Y, He Y. · · 2025 · cited 1× · PMID 41112246 · DOI 10.3389/fimmu.2025.1658681

Verify or expand the search:

Other recruiting trials for Esophageal Carcinoma

Currently open trials in the same condition.

NCT07283939 — Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · NA · recruiting
NCT07108855 — Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green Duri · Phase 1, PHASE2 · recruiting
NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
NCT06872515 — Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal) · NA · recruiting
NCT06995898 — The Vanguard Study: Testing a New Way to Screen for Cancer · NA · recruiting

Other Hebei Medical University Fourth Hospital trials

Trials by the same sponsor.

NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
NCT07448077 — Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC · Phase 2 · not yet recruiting
NCT07410611 — ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy · Phase 2 · not yet recruiting
NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting
NCT07492394 — Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05952661 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hebei Medical University Fourth Hospital
Last refreshed: 19 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05952661.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing